RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Core Points - RAPT Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the total shares offered [1] - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1] - The offering is made under a shelf registration statement filed with the SEC, which was declared effective on August 17, 2023 [3] Company Overview - RAPT is a clinical-stage immunology-based biopharmaceutical company focused on developing novel therapies for inflammatory and immunological diseases [5] - The company utilizes proprietary expertise in immunology to create therapies aimed at modulating critical immune responses [5] Offering Details - Joint bookrunning managers for the offering include Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital [2] - Lead managers for the offering are H.C. Wainwright & Co. and Clear Street [2] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]